publication . Article . 2015

Participation in HIV cure-related research: a scoping review of the proxy literature and implications for future research

Dubé, Karine; Ramirez, Catalina; Handibode, Jessica; Taylor, Jeffrey; Skinner, Asheley; Greene, Sandra; Tucker, Joseph D;
Open Access English
  • Published: 01 Oct 2015 Journal: Journal of Virus Eradication, volume 1, issue 4, pages 250-256 (issn: 2055-6640, eissn: 2055-6659, Copyright policy)
  • Publisher: Mediscript Ltd
Abstract
Abstract Objective To identify the main types of HIV cure-related strategies and examine possible risks (and benefits) associated with participating in HIV cure-related research studies. Methods We undertook a scoping review to first map out the landscape of HIV cure-related research and then examined the risks and potential benefits associated with participating in HIV cure research. Given the early stage of many HIV cure-related studies, we used proxy literatures from non-cure HIV research and cancer research in order to anticipate possible motivators and deterrents of participation in HIV cure-related studies. Results We discussed four main categories of HIV ...
Subjects
Medical Subject Headings: virus diseases
free text keywords: Review, HIV cure-related research, willingness to participate, social sciences
Funded by
NIH| UNC Center for Aids Research
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5P30AI050410-05
  • Funding stream: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
44 references, page 1 of 3

1.Allers K, Hütter G, Hofmann J et al.Evidence for the cure of HIV infection by CCR5Δ32/Δ32 s tem cell transplantation. Blood 2011; 117: 2791– 2799.21148083 [OpenAIRE] [PubMed]

2.Luzuriaga K, Gay H, Siemniak C et al.Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med 2015; 372: 784– 786. [OpenAIRE]

3.Henrich TJ, Hanhauser E, Hu Z et al.Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32. AIDS 2015; 29: 867– 876.25730507 [OpenAIRE] [PubMed]

4.TAG Research towards a cure trials. Available at: www.treatmentactiongroup.org/cure/trials (accessed September 2015).

5.Dhalla S, Poole G Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. AIDS Care 2011; 23: 1430– 1447.21722022 [OpenAIRE] [PubMed]

6.Dhalla S, Poole G Motivators to participation in actual HIV vaccine trials. AIDS Behav 2014; 18: 263– 277.23736885 [OpenAIRE] [PubMed]

7.Buchbinder SP, Metch B, Holte SE et al.Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr 2004; 36: 604– 612.15097304 [OpenAIRE] [PubMed]

8.Tucker J, Volberding P, Margolis D et al.Words matter: discussing research towards an HIV cure research and clinical contexts. J Acquir Immune Defic Syndr 2014; 67: e110– e111.25314254 [OpenAIRE] [PubMed]

9.DubéK, Henderson GE, Margolis DM Framing expectations in early HIV cure research. Trends Microbiol 2014; 22: 547– 549.25280965 [OpenAIRE] [PubMed]

10.Armstrong R, Hall BJ, Doyle J, Waters E ‘ Scoping the scope’ of a Cochrane review. J Pub Health 2011; 33: 147– 150.

11.Ananworanich J, DubéK, Chomont N How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?Curr Opinion HIV AIDS 2015; 10: 18– 28. [OpenAIRE]

12.Bell SK, Little SJ, Rosenberg ES Clinical management of acute HIV infection: best practice remains unknown. J Infect Dis 2010; 202: S278– 288.20846034 [OpenAIRE] [PubMed]

13.Henrich TJ, Gandhi RT Early treatment and HIV-1 reservoirs: a stitch in time?J Infect Dis 2013; 208: 1189– 1193.23852126 [OpenAIRE] [PubMed]

14.Ananworanich J, Vandergeeten C, Schuetz A et al.HIV reservoir size and immunity in blood and sigmoid colon of acute HIV-infected Thai subjects following 5- and 3-drug HAART. Conference on Retroviruses and Opportunistic Infections. March 2012 Seattle, WA, USA. Abstract 363.

15.Sáez-Cirión A, Bacchus C, Hocqueloux L et al.Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Path 2013; 9: e1003211.

44 references, page 1 of 3
Abstract
Abstract Objective To identify the main types of HIV cure-related strategies and examine possible risks (and benefits) associated with participating in HIV cure-related research studies. Methods We undertook a scoping review to first map out the landscape of HIV cure-related research and then examined the risks and potential benefits associated with participating in HIV cure research. Given the early stage of many HIV cure-related studies, we used proxy literatures from non-cure HIV research and cancer research in order to anticipate possible motivators and deterrents of participation in HIV cure-related studies. Results We discussed four main categories of HIV ...
Subjects
Medical Subject Headings: virus diseases
free text keywords: Review, HIV cure-related research, willingness to participate, social sciences
Funded by
NIH| UNC Center for Aids Research
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5P30AI050410-05
  • Funding stream: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
44 references, page 1 of 3

1.Allers K, Hütter G, Hofmann J et al.Evidence for the cure of HIV infection by CCR5Δ32/Δ32 s tem cell transplantation. Blood 2011; 117: 2791– 2799.21148083 [OpenAIRE] [PubMed]

2.Luzuriaga K, Gay H, Siemniak C et al.Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med 2015; 372: 784– 786. [OpenAIRE]

3.Henrich TJ, Hanhauser E, Hu Z et al.Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32. AIDS 2015; 29: 867– 876.25730507 [OpenAIRE] [PubMed]

4.TAG Research towards a cure trials. Available at: www.treatmentactiongroup.org/cure/trials (accessed September 2015).

5.Dhalla S, Poole G Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. AIDS Care 2011; 23: 1430– 1447.21722022 [OpenAIRE] [PubMed]

6.Dhalla S, Poole G Motivators to participation in actual HIV vaccine trials. AIDS Behav 2014; 18: 263– 277.23736885 [OpenAIRE] [PubMed]

7.Buchbinder SP, Metch B, Holte SE et al.Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr 2004; 36: 604– 612.15097304 [OpenAIRE] [PubMed]

8.Tucker J, Volberding P, Margolis D et al.Words matter: discussing research towards an HIV cure research and clinical contexts. J Acquir Immune Defic Syndr 2014; 67: e110– e111.25314254 [OpenAIRE] [PubMed]

9.DubéK, Henderson GE, Margolis DM Framing expectations in early HIV cure research. Trends Microbiol 2014; 22: 547– 549.25280965 [OpenAIRE] [PubMed]

10.Armstrong R, Hall BJ, Doyle J, Waters E ‘ Scoping the scope’ of a Cochrane review. J Pub Health 2011; 33: 147– 150.

11.Ananworanich J, DubéK, Chomont N How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?Curr Opinion HIV AIDS 2015; 10: 18– 28. [OpenAIRE]

12.Bell SK, Little SJ, Rosenberg ES Clinical management of acute HIV infection: best practice remains unknown. J Infect Dis 2010; 202: S278– 288.20846034 [OpenAIRE] [PubMed]

13.Henrich TJ, Gandhi RT Early treatment and HIV-1 reservoirs: a stitch in time?J Infect Dis 2013; 208: 1189– 1193.23852126 [OpenAIRE] [PubMed]

14.Ananworanich J, Vandergeeten C, Schuetz A et al.HIV reservoir size and immunity in blood and sigmoid colon of acute HIV-infected Thai subjects following 5- and 3-drug HAART. Conference on Retroviruses and Opportunistic Infections. March 2012 Seattle, WA, USA. Abstract 363.

15.Sáez-Cirión A, Bacchus C, Hocqueloux L et al.Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Path 2013; 9: e1003211.

44 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue